NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Krystal Biotech, Inc. KRYS
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$389.1M
▲ 33.9% vs FY2024
EPS · FY25
$6.84
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
18.9%
Net margin · FY25
52.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 389.1M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
53 cents of every revenue dollar became profit this year.
Per share
USD 6.84
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
18.9%
Return on equity, FY2025
ROE
Operating margin41.5%
Net margin52.6%
Return on assets17.1%
Each USD of equity produced 19 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+48.1%
Change, 10 years—
The share count grew 48% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.3B
total assets, end of FY2025
Total assetsUSD 1.3B
EquityUSD 1.2B
CashUSD 496.3M
Current ratio9.95×
Equity funds 91% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.4
0.3
0.1
0.0
0.0
·
·
·
·
·
Operating income $B
0.2
0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.2
0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
0.2
0.1
0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
6.84
3.00
0.39
−5.49
−3.13
−1.71
−1.20
−0.97
−1.48
−1.31
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
18.9
10.3
1.7
−25.1
−15.7
−13.0
−12.1
−13.4
−31.8
−397.9
Shares out B
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
30 of 30
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed